SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-343645"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-343645" >

COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer.

Gulyas, Miklos (författare)
Uppsala universitet,Klinisk och experimentell patologi,Genetics and Pathology , Uppsala University , Uppsala , Sweden
Mattsson, Johanna Sofia Margareta, 1985- (författare)
Uppsala universitet,Klinisk och experimentell patologi,Patrick Micke,Genetics and Pathology , Uppsala University , Uppsala , Sweden
Lindgren, Andrea (författare)
Linköpings universitet,Avdelningen för kardiovaskulär medicin,Medicinska fakulteten,Region Östergötland, Allergicentrum US
visa fler...
Ek, Lars (författare)
Skåne Univ Hosp, Pulm Med, Lund,Skane University Hospital , Lund , Sweden
Lamberg Lundström, Kristina (författare)
Akad Hosp, Pulm Med, Uppsala,Akademiska Hospital , Uppsala , Sweden
Behndig, Annelie (författare)
Norrland Univ Hosp, Pulm Med, Umeå,Norrland University Hospital , Umeå , Sweden
Holmberg, Erik (författare)
Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Oncol, Gothenburg,Sahlgrenska Academy at University of Gothenburg , Sweden
Micke, Patrick (författare)
Uppsala universitet,Klinisk och experimentell patologi,Patrick Micke,Genetics and Pathology , Uppsala University , Uppsala , Sweden
Bergman, Bengt (författare)
Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Resp Med,Sahlgrenska Academy at University of Gothenburg , Sweden.
visa färre...
 (creator_code:org_t)
Taylor & Francis, 2018
Engelska.
Ingår i: Acta Oncologica. - : Taylor & Francis. - 0284-186X .- 1651-226X. ; 57:2, s. 244-250
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Aim: Inhibition of cyclooxygenase-2 (COX-2) is proposed as a treatment option in several cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have failed to demonstrate a benefit of adding COX-2 inhibitors to standard chemotherapy. The aim of this study was to analyze COX-2 expression in tumor and stromal cells as predictive biomarker for COX-2 inhibition.Methods: In a multicenter phase III trial, 316 patients with advanced NSCLC were randomized to receive celecoxib (400 mg b.i.d.) or placebo up to one year in addition to a two-drug platinum-based chemotherapy combination. In a subset of 122 patients, archived tumor tissue was available for immunohistochemical analysis of COX-2 expression in tumor and stromal cells. For each compartment, COX-2 expression was graded as high or low, based on a product score of extension and intensity of positively stained cells.Results: An updated analysis of all 316 patients included in the original trial, and of the 122 patients with available tumor tissue, showed no survival differences between the celecoxib and placebo arms (HR 1.01; 95% CI 0.81–1.27 and HR 1.12; 95% CI 0.78–1.61, respectively). High COX-2 scores in tumor (n = 71) or stromal cells (n = 55) was not associated with a superior survival outcome with celecoxib vs. placebo (HR =0.96, 95% CI 0.60–1.54; and HR =1.51; 95% CI 0.86–2.66), and no significant interaction effect between COX-2 score in tumor or stromal cells and celecoxib effect on survival was detected (p = .48 and .25, respectively).Conclusions: In this subgroup analysis of patients with advanced NSCLC treated within the context of a randomized trial, we could not detect any interaction effect of COX-2 expression in tumor or stromal cells and the outcome of celecoxib treatment in addition to standard chemotherapy.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Klinisk laboratoriemedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Clinical Laboratory Medicine (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Lungmedicin och allergi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Respiratory Medicine and Allergy (hsv//eng)

Nyckelord

Patologi
Pathology

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy